Gensight Biologics : Visibility hinges on the AAC start-up
>Cash runway out to Q3 2025 - Gensight reported its H1 2024 results, the main takeaways from which are as follows: 1/ a decrease in R&D spending of 46% to € 6.3m due to the focus on the Lumevoq project at the expense of GS030 and lower spending in CMC businesses, and 2/ a reduction in SG&A costs of 63% to € 0.3m particularly reflecting the withdrawal of the marketing authorisation application for Lumevoq with the EMA and the termination of preparations for the product...GenSight Biologics is a clinical-stage biotechnology company based in France. Co. is engaged in discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system by combining a gene therapy-based approach with its core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics. Co.'s initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases. Co.'s product pipeline comprises two candidates for the treatment of sight-threatening retinal degenerative diseases, GSO1O and GSO3O.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.